CA3048186A1 - Anti-il-5 antibodies - Google Patents
Anti-il-5 antibodies Download PDFInfo
- Publication number
- CA3048186A1 CA3048186A1 CA3048186A CA3048186A CA3048186A1 CA 3048186 A1 CA3048186 A1 CA 3048186A1 CA 3048186 A CA3048186 A CA 3048186A CA 3048186 A CA3048186 A CA 3048186A CA 3048186 A1 CA3048186 A1 CA 3048186A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- acid sequence
- seq
- light chain
- antibody molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438502P | 2016-12-23 | 2016-12-23 | |
| US62/438,502 | 2016-12-23 | ||
| PCT/US2017/067475 WO2018119016A1 (en) | 2016-12-23 | 2017-12-20 | Anti-il-5 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3048186A1 true CA3048186A1 (en) | 2018-06-28 |
Family
ID=60972458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3048186A Pending CA3048186A1 (en) | 2016-12-23 | 2017-12-20 | Anti-il-5 antibodies |
Country Status (20)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201991552A1 (ru) * | 2016-12-23 | 2020-01-09 | Сефалон, Инк. | Анти-il-5 антитела |
| SMT202600240T1 (it) | 2017-05-26 | 2026-07-16 | Glaxosmithkline Ip Dev Ltd | Composizioni biofarmaceutiche e metodi correlati |
| CN113366016B (zh) * | 2018-12-12 | 2022-12-16 | 上海开拓者生物医药有限公司 | 抗人白细胞介素5(il-5)单克隆抗体及其应用 |
| JP7641908B2 (ja) | 2019-03-29 | 2025-03-07 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用 |
| CN112745389B (zh) * | 2019-10-29 | 2022-11-25 | 瑞阳(苏州)生物科技有限公司 | 结合人il-5的单克隆抗体及其应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6056957A (en) * | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| US5683892A (en) * | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| JP2001523083A (ja) * | 1994-12-23 | 2001-11-20 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| ES2327830T3 (es) * | 2002-03-29 | 2009-11-04 | Schering Corporation | Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen. |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| ES3053874T3 (en) | 2015-08-24 | 2026-01-27 | Glaxosmithkline Ip No 2 Ltd | Biopharmaceutical compositions |
| EP3365369A1 (en) * | 2015-10-23 | 2018-08-29 | Pfizer Inc | Anti-il-2 antibodies and compositions and uses thereof |
| EA201991552A1 (ru) * | 2016-12-23 | 2020-01-09 | Сефалон, Инк. | Анти-il-5 антитела |
-
2017
- 2017-12-20 EA EA201991552A patent/EA201991552A1/ru unknown
- 2017-12-20 BR BR112019012929-4A patent/BR112019012929A2/pt active Search and Examination
- 2017-12-20 PE PE2019001295A patent/PE20191662A1/es unknown
- 2017-12-20 CN CN201780079923.2A patent/CN110267986B/zh active Active
- 2017-12-20 WO PCT/US2017/067475 patent/WO2018119016A1/en not_active Ceased
- 2017-12-20 US US15/848,090 patent/US11111292B2/en active Active
- 2017-12-20 CA CA3048186A patent/CA3048186A1/en active Pending
- 2017-12-20 JP JP2019534656A patent/JP7060906B2/ja active Active
- 2017-12-20 ES ES17829503T patent/ES2984636T3/es active Active
- 2017-12-20 KR KR1020197021088A patent/KR102651290B1/ko active Active
- 2017-12-20 AR ARP170103611A patent/AR110564A1/es not_active Application Discontinuation
- 2017-12-20 EP EP17829503.6A patent/EP3559030B1/en active Active
- 2017-12-20 MX MX2019007642A patent/MX2019007642A/es unknown
- 2017-12-20 RU RU2019123112A patent/RU2758008C2/ru active
- 2017-12-20 AU AU2017379853A patent/AU2017379853B2/en active Active
- 2017-12-20 IL IL267271A patent/IL267271B2/en unknown
- 2017-12-20 NZ NZ754606A patent/NZ754606A/en unknown
-
2019
- 2019-06-20 CL CL2019001730A patent/CL2019001730A1/es unknown
- 2019-06-21 PH PH12019501452A patent/PH12019501452A1/en unknown
- 2019-06-24 ZA ZA2019/04097A patent/ZA201904097B/en unknown
-
2021
- 2021-07-26 US US17/385,532 patent/US12577298B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210355205A1 (en) | 2021-11-18 |
| EP3559030A1 (en) | 2019-10-30 |
| MX2019007642A (es) | 2019-09-09 |
| ZA201904097B (en) | 2023-12-20 |
| WO2018119016A1 (en) | 2018-06-28 |
| PE20191662A1 (es) | 2019-11-11 |
| EP3559030B1 (en) | 2024-04-03 |
| IL267271B2 (en) | 2025-10-01 |
| JP2020513761A (ja) | 2020-05-21 |
| AR110564A1 (es) | 2019-04-10 |
| CN110267986B (zh) | 2023-05-09 |
| JP7060906B2 (ja) | 2022-04-27 |
| AU2017379853A1 (en) | 2019-07-04 |
| ES2984636T3 (es) | 2024-10-30 |
| IL267271A (en) | 2019-08-29 |
| US20180186873A1 (en) | 2018-07-05 |
| RU2019123112A3 (cg-RX-API-DMAC7.html) | 2021-04-05 |
| RU2019123112A (ru) | 2021-01-26 |
| US12577298B2 (en) | 2026-03-17 |
| NZ754606A (en) | 2023-06-30 |
| EP3559030C0 (en) | 2024-04-03 |
| US11111292B2 (en) | 2021-09-07 |
| KR102651290B1 (ko) | 2024-03-25 |
| PH12019501452A1 (en) | 2020-06-15 |
| EA201991552A1 (ru) | 2020-01-09 |
| AU2017379853B2 (en) | 2025-02-06 |
| CN110267986A (zh) | 2019-09-20 |
| KR20190126769A (ko) | 2019-11-12 |
| BR112019012929A2 (pt) | 2019-12-10 |
| IL267271B1 (en) | 2025-06-01 |
| CL2019001730A1 (es) | 2019-09-27 |
| RU2758008C2 (ru) | 2021-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12577298B2 (en) | Anti-IL-5 antibodies | |
| US12410247B2 (en) | Polynucleotides encoding antibodies that specifically bind to human IL-15 | |
| AU2023203440B2 (en) | Antibodies that specifically bind to TL1A | |
| AU2012328921B2 (en) | Immunobinders directed against TNF | |
| JP2025522482A (ja) | インターロイキン１３に結合する抗体及び使用方法 | |
| US11028164B2 (en) | Anti-CXCL13 antibodies | |
| JP2026514143A (ja) | Ｏｘ４０ｌに結合する抗体及びその使用方法 | |
| JP2023076596A (ja) | ＴＧＦ－βＲＩＩ結合タンパク質 | |
| WO2024200854A1 (en) | Allergen binding antibodies suitable for treating tree pollen allergies | |
| WO2022061236A1 (en) | High affinity anti-ige antibodies | |
| CA3236108A1 (en) | Galectin-10 antibodies | |
| HK40015055B (en) | Anti-il-5 antibodies | |
| HK40015055A (en) | Anti-il-5 antibodies | |
| EA042576B1 (ru) | Анти-il-5 антитела | |
| US20260109769A1 (en) | Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use | |
| US20220204613A1 (en) | Anti-cd47 antibodies and uses thereof | |
| HK40129159A (en) | Antibodies that specifically bind to human il-15 and uses thereof | |
| HK40013673A (en) | Antibodies that specifically bind to human il-15 and uses thereof | |
| HK40013673B (en) | Antibodies that specifically bind to human il-15 and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221215 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20240802 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241007 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241209 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250123 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250605 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250605 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250813 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250813 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251106 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251212 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260306 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260309 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260309 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260309 |